China Medical System Holdings Limited (00867.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 11.03

From 52W high−28.35%

Volume7.35M

Market capHKD 26.78B

P/E (TTM)15.3x

P/S (TTM)2.6x

Div yield3.11%

Key dataSep 18, 2026

Open

HKD 11.03

From 52W high

−28.35%

Volume

7.35M

Market cap

HKD 26.78B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.1x

P/E (TTM)

15.3x

RSI (14)

44.8

MomentumView details →

1D Return

+0.18%

YTD Return

−14.19%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

15.3x

EV/EBITDA

9.1x

EV/Sales

2.1x

P/S (TTM)

2.6x

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

71.18%

Net Margin

17.58%

EBITDA Margin

23.07%

ROE (TTM)

8.47%

ROA (TTM)

7.73%

Asset Turnover

0.44x

GrowthView details →

Revenue YoY

+10.04%

EPS YoY

−8.82%

FCF YoY

−0.36%

Revenue CAGR 3Y

−3.54%

EPS CAGR 3Y

−22.46%

EBITDA YoY

−13.40%

MomentumView details →

1D Return

+0.18%

YTD Return

−14.19%

1Y Return

−26.30%

RSI (14)

44.8

vs 50D SMA

−5.43%

vs 200D SMA

−12.46%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

6.64x

Quick Ratio

5.97x

Div Yield

3.11%

Div Rate

HKD 0.34

Div Growth 1Y

+15.44%

EarningsView details →

EPS (Actual)

HKD 0.47

EPS Surprise

1.88%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

1.88%

Rev Surprise

−5.09%

Financials snapshotView financials →

Revenue (TTM)

16.51B

Net Income (TTM)

3.17B

Op. CF (TTM)

1.99B

Next earningsMar 16, 2027 →

Latest newsMore news →

China Medical System Holdings announced that its self-developed highly selective TYK2 inhibitor CMS-D001 received approval from China's NMPA on September 11, 2026 for a clinical trial in systemic lupus erythematosus, with the notice received on September 14, 2026.7d ago

China Medical System announced that its Class 1 innovative drug Jinsuxi (sirukumab injection), the world's first rabies bispecific antibody, has been prescribed at multiple hospitals across China, marking the start of large-scale clinical use.12d ago

Similar companies

China Resources Pharmaceutical Group Limited03320.HK 达仁堂600329.SH ST人福600079.SH Zoetis Inc.ZTS 华海药业600521.SH The United Laboratories International Holdings Limited03933.HK Find similar companies →

Latest newsMore news →

China Medical System Holdings announced that its self-developed highly selective TYK2 inhibitor CMS-D001 received approval from China's NMPA on September 11, 2026 for a clinical trial in systemic lupus erythematosus, with the notice received on September 14, 2026.7d ago China Medical System announced that its Class 1 innovative drug Jinsuxi (sirukumab injection), the world's first rabies bispecific antibody, has been prescribed at multiple hospitals across China, marking the start of large-scale clinical use.12d ago